BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34520088)

  • 1. All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy.
    Lockart I; Hajarizadeh B; Buckley N; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3515-3523. PubMed ID: 34520088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of transplantation for HBV- vs. HCV-related HCC: impact of DAA HCV therapy in a national analysis of >20,000 patients.
    Tabrizian P; Saberi B; Holzner ML; Rocha C; Kyung Jung Y; Myers B; Florman SS; Schwartz ME
    HPB (Oxford); 2022 Jul; 24(7):1082-1090. PubMed ID: 34955348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era.
    Shaikh A; Goli K; Lee TH; Rich NE; Benhammou JN; Keeling S; Kim D; Ahmed A; Goss J; Rana A; Singal AG; Kanwal F; Cholankeril G
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2288-2297.e4. PubMed ID: 36521738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
    Singal AG; Rich NE; Mehta N; Branch AD; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Ioannou GN; Huang A; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Kagan S; Gopal P; Wong R; Parikh ND; Murphy CC
    Gastroenterology; 2019 Nov; 157(5):1253-1263.e2. PubMed ID: 31374215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND
    Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival.
    Lockart I; Hajarizadeh B; Alavi M; Davison S; Prakoso E; Levy MT; George J; Dore GJ; Danta M
    J Viral Hepat; 2021 May; 28(5):710-718. PubMed ID: 33481322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West.
    Dang H; Yeo YH; Yasuda S; Huang CF; Iio E; Landis C; Jun DW; Enomoto M; Ogawa E; Tsai PC; Le A; Liu M; Maeda M; Nguyen B; Ramrakhiani N; Henry L; Cheung R; Tamori A; Kumada T; Tanaka Y; Yu ML; Toyoda H; Nguyen MH
    Hepatology; 2020 Jun; 71(6):1910-1922. PubMed ID: 31610027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Kwong AJ; Kim WR; Flemming JA
    Hepatology; 2018 Oct; 68(4):1288-1297. PubMed ID: 29672886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
    Ochi H; Hiraoka A; Hirooka M; Koizumi Y; Amano M; Azemoto N; Watanabe T; Yoshida O; Tokumoto Y; Mashiba T; Yokota T; Abe M; Michitaka K; Hiasa Y; Joko K
    J Gastroenterol; 2021 Jan; 56(1):90-100. PubMed ID: 33278003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.
    Younossi ZM; Stepanova M; Saab S; Ahmed A; Lam B; Srishord M; Venkatesan C; Wai H; Henry L
    J Viral Hepat; 2016 Jan; 23(1):53-61. PubMed ID: 26289820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
    Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
    J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
    Mashiba T; Joko K; Kurosaki M; Ochi H; Marusawa H; Uchida Y; Fujii H; Kojima Y; Yoshida H; Goto T; Akahane T; Kondo M; Tsuji K; Mitsuda A; Hasebe C; Kusakabe A; Sohda T; Furuta K; Kobashi H; Ogawa C; Ide Y; Arai H; Okada K; Shigeno M; Nonogi R; Izumi N
    J Viral Hepat; 2022 Jul; 29(7):551-558. PubMed ID: 35548866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower Likelihood of Post-transplant Graft Failure, Death, and Retransplantation in the Era of Direct-Acting Antivirals.
    Young K; Liu B; Bhuket T; Wong RJ
    J Clin Exp Hepatol; 2020; 10(6):581-589. PubMed ID: 33311895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Liver Transplant Outcomes for Hepatitis C Virus Hepatocellular Carcinoma in the Direct-Acting Antiviral Therapy Era.
    Okumura K; Sogawa H; Samson D; Butler J; Veillette G; John D; Diflo T; Bodin R; Wolf DC; Latifi R; Nishida S
    Transplant Proc; 2022 Sep; 54(7):1834-1838. PubMed ID: 35933231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
    Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
    Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.